This week's Fierce Pharma is brought to you by Databricks.

Complimentary Whitepaper Download

Hi E, check out this Fierce whitepaper we think you'll like:

Encouraged by their early successes, biopharma companies are now committed to investing in RWE to increase speed to market, reduce trial costs and realize a host of other benefits. Yet, companies continue to grapple with technology challenges that are impeding their efforts to deliver the benefits of RWE.

Recognizing this, Databricks surveyed 109 biopharma executives to generate insights into how the industry is approaching RWE. The survey primarily captured the views of people working in R&D, analytics/data science and real-world evidence at the level of senior manager and above, making the results a snapshot of the thinking of RWE decision makers in the biopharma industry.